Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Burden

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
The British Journal of Dermatology|October 20, 2019
Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE)R B Warren, J N W B Barker, A Y Finlay, et al.
The British Journal of Dermatology|August 30, 2018
Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort studyR B Warren, A Marsden, B Tomenson, et al.
The British Journal of Dermatology|September 3, 2016
Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)I Y K Iskandar, D M Ashcroft, R B Warren, et al.
Journal of Medical Genetics|November 13, 2007
Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn diseaseN Wolf, M Quaranta, N J Prescott, et al.
The British Journal of Dermatology|January 26, 2006
Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretinE Campalani, M H Allen, D Fairhurst, et al.
The British Journal of Dermatology|March 2, 2019
A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasisZ Z N Yiu, K J Mason, J N W N Barker, et al.
Experimental Dermatology|August 22, 2003
A Crohn's disease-associated insertion polymorphism (3020insC) in the NOD2 gene is not associated with psoriasis vulgaris, palmo-plantar pustular psoriasis or guttate psoriasisC Young, M H Allen, A Cuthbert, et al.
The British Journal of Dermatology|July 10, 2019
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)S K Mahil, N Wilson, N Dand, et al.
Journal of Medical Genetics|January 3, 2001
Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate lociC D Veal, R L Clough, R C Barber, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 16, 2021
Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIRK J Mason, A D Burden, J N W N Barker, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
The British Journal of Dermatology|October 20, 2019
Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE)R B Warren, J N W B Barker, A Y Finlay, et al.
The British Journal of Dermatology|August 30, 2018
Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort studyR B Warren, A Marsden, B Tomenson, et al.
The British Journal of Dermatology|September 3, 2016
Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)I Y K Iskandar, D M Ashcroft, R B Warren, et al.
Journal of Medical Genetics|November 13, 2007
Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn diseaseN Wolf, M Quaranta, N J Prescott, et al.
The British Journal of Dermatology|January 26, 2006
Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretinE Campalani, M H Allen, D Fairhurst, et al.
The British Journal of Dermatology|March 2, 2019
A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasisZ Z N Yiu, K J Mason, J N W N Barker, et al.
Experimental Dermatology|August 22, 2003
A Crohn's disease-associated insertion polymorphism (3020insC) in the NOD2 gene is not associated with psoriasis vulgaris, palmo-plantar pustular psoriasis or guttate psoriasisC Young, M H Allen, A Cuthbert, et al.
The British Journal of Dermatology|July 10, 2019
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)S K Mahil, N Wilson, N Dand, et al.
Journal of Medical Genetics|January 3, 2001
Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate lociC D Veal, R L Clough, R C Barber, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 16, 2021
Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIRK J Mason, A D Burden, J N W N Barker, et al.
Pageof 12